

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	09/802,094
	Filing Date	March 3, 2001
	First Named Inventor	Paul Calabresi
	Group Art Unit	1642 1614
	Examiner Name	C. Yaeu Unknown
	Attorney Docket Number	21486-038

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
CY	AA	6,100,273	8/8/00	Besterman et al.	514	279	
CY	AB	5,192,744	3/9/93	Bouck et al.	514	8	
CY	AC	5,840,692	11/24/98	Deutch et al.	514	12	

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
CY	BA	WO	9954445 A2	Joshi et al.	10/24/99		
CY	BB	WO	9910525 A1	Heimbrook et al.	03/04/99		
CY	BC	WO	9910524 A1	Burkhardt et al.	03/04/99		
CY	BD	WO	9910523 A1	Barnett et al.	03/04/99		
CY	BE	WO	9843618 A2	Kunz et al.	10/08/98		
CY	BF	WO	9601127 A1	Ratain et al.	01/18/96		

OTHER NON PATENT LITERATURE DOCUMENTS			
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.	
CY	CA	Clements et al., "Antiangiogenic potential of camptothecin and topotecan," 1999, Cancer Chemotherapy and Pharmacology, V44, N1, p. 39-48.	
CY	CB	Clements et al., "Inhibition of Angiogenesis and Proliferation of Normal Endothelial Cells by Camptothecin," 1998, FASEB J., N5, 2, S(March 20), p. 5499	
CY	CC	Clements et al., "Camptothecin exhibits selective cytotoxicity towards human breast carcinoma as compared to normal bovine endothelial cells <i>in vitro</i> ," 1996, Anticancer Drugs 7:851.	
CY	CD	Guo et al., "Thrombospondin 1 and Type I Repeat Peptides of Thrombospondin 1 Specifically Induce Apoptosis of Endothelial Cells," Cancer Res. 57/9 (1735-1742).	
CY	CE	Hsiang et al., "DNA Topoisomerase I-mediated DNA Cleavage and Cytotoxicity of Camptothecin Analogues," 1989, Cancer Research, 49:4385-4389.	
CY	CF	Jaxel et al., "Structure-Activity Study of the Actions of Camptothecin Derivatives on Mammalian Topoisomerase I: Evidence for a Specific Receptor Site and a Relation to Antitumor Activity," Cancer Research, 49:1465-1469.	
	CG	Kakeji et al., "Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents," Investigational New Drugs, 7(1):39-48	
Examiner Signature		Chris L. H. H. H.	Date Considered 3/17/03



EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

RECEIVED

DEC 27 2002

TECH CENTER 1600/2900



Modified Form 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	09/802,094
Filing Date	March 3, 2001
First Named Inventor	Paul Calabresi
Group Art Unit	1614 1642
Examiner Name	Unknown C-Yaen
Attorney Docket Number	21486-038

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
CY	AD	5,994,309	09/30/99	Mazar et al.	514	16	
CY	AE	5,994,341	09/30/99	Hunter et al.	514	210	
CY	AF	5,981,568	09/09/99	Kunz et al.	514	411	
CY	AG	5,886,026	03/23/99	Hunter et al.	514	449	
CY	AH	5,843,994	12/01/98	Samid	514	510	
CY	AI	5,786,344	07/28/98	Ratain et al.	514	100	
CY	AJ	5,670,507	09/23/97	Rice et al.	514	263	

OTHER NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
CY	CH	Kantarjian et al., "New Developments in the Treatment of Acute Myeloid Leukemia: Focus on Topotecan," Seminars in Hematology, 36/4 Suppl. 8 (16-5).
CY	CI	O'Leary et al., "Antiangiogenic Effects of Camptothecin Analogues 9-Amino-20(S)-camptothecin, Topotecan, and CPT-11 Studies in the Mouse," 1999, Clinical Cancer Research, 5:181-7
CY	CJ	Polverini et al., "Assay and Purification of Naturally Occurring Inhibitor of Angiogenesis," 1991, Methods. Enzymol. 198:440-450.
Examiner Signature	Chouyph H L	Date Considered 3/17/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

TRA 1530658v2

RECEIVED
DEC 27 2002
TECH CENTER 1600/2900